JP2010526543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526543A5 JP2010526543A5 JP2010507770A JP2010507770A JP2010526543A5 JP 2010526543 A5 JP2010526543 A5 JP 2010526543A5 JP 2010507770 A JP2010507770 A JP 2010507770A JP 2010507770 A JP2010507770 A JP 2010507770A JP 2010526543 A5 JP2010526543 A5 JP 2010526543A5
- Authority
- JP
- Japan
- Prior art keywords
- alkaline phosphatase
- amino acid
- seq
- cell
- salp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 36
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 36
- 125000000539 amino acid group Chemical group 0.000 claims 13
- 150000001413 amino acids Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 4
- 230000033558 biomineral tissue development Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 206010058314 Dysplasia Diseases 0.000 claims 3
- 229920000805 Polyaspartic acid Polymers 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010064470 polyaspartate Proteins 0.000 claims 3
- 210000002700 urine Anatomy 0.000 claims 3
- KJBQDYDTQCIAFO-ZLELNMGESA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2,6-diaminohexanoic acid Chemical group CC(C)C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O KJBQDYDTQCIAFO-ZLELNMGESA-N 0.000 claims 2
- SEFLNGWGXSFZMH-DQZFIDPSSA-N (2s)-2-aminobutanedioic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical group CC[C@H](C)[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC(O)=O SEFLNGWGXSFZMH-DQZFIDPSSA-N 0.000 claims 2
- 241000699802 Cricetulus griseus Species 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims 2
- 230000018678 bone mineralization Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000029663 Hypophosphatemia Diseases 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 210000001750 dental cementum Anatomy 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001872 metatarsal bone Anatomy 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 208000007442 rickets Diseases 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 210000002303 tibia Anatomy 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91758907P | 2007-05-11 | 2007-05-11 | |
| US60/917,589 | 2007-05-11 | ||
| PCT/CA2008/000923 WO2008138131A1 (en) | 2007-05-11 | 2008-05-12 | Bone targeted alkaline phosphatase, kits and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526543A JP2010526543A (ja) | 2010-08-05 |
| JP2010526543A5 true JP2010526543A5 (enExample) | 2011-06-30 |
| JP5732603B2 JP5732603B2 (ja) | 2015-06-10 |
Family
ID=40001639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507770A Active JP5732603B2 (ja) | 2007-05-11 | 2008-05-12 | 骨標的アルカリホスファターゼ、キット及びその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20100297119A1 (enExample) |
| EP (3) | EP2662448B1 (enExample) |
| JP (1) | JP5732603B2 (enExample) |
| AT (1) | ATE536413T1 (enExample) |
| AU (1) | AU2008250945B2 (enExample) |
| BR (2) | BRPI0811198B8 (enExample) |
| CA (1) | CA2687001C (enExample) |
| CY (1) | CY2016005I1 (enExample) |
| DE (1) | DE202008018131U1 (enExample) |
| DK (3) | DK2158319T3 (enExample) |
| ES (3) | ES2380546T3 (enExample) |
| FR (1) | FR16C0007I2 (enExample) |
| HR (1) | HRP20140416T1 (enExample) |
| HU (2) | HUE031655T2 (enExample) |
| IL (1) | IL202057A0 (enExample) |
| LT (1) | LTC2368999I2 (enExample) |
| LU (1) | LU92976I2 (enExample) |
| ME (1) | ME01828B (enExample) |
| NL (1) | NL300798I1 (enExample) |
| NO (1) | NO2016002I2 (enExample) |
| PL (3) | PL2158319T4 (enExample) |
| PT (3) | PT2368999E (enExample) |
| RS (1) | RS53302B (enExample) |
| SI (2) | SI2662448T1 (enExample) |
| WO (1) | WO2008138131A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055861T2 (hu) * | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| US8784833B2 (en) * | 2006-06-27 | 2014-07-22 | Saint Louis University | Prenatal enzyme replacement therapy for hypophosphatasia |
| EP2185589B1 (en) | 2007-06-01 | 2016-01-06 | University of Maryland, Baltimore | Immunoglobulin constant region fc receptor binding agents |
| WO2011113027A2 (en) | 2010-03-12 | 2011-09-15 | Synageva Biopharma Corp | Npp1 fusion proteins |
| AU2011245005A1 (en) * | 2010-04-30 | 2012-11-22 | Alexion Pharma Holding | Methods, compositions, and kits for the treatment of matrix mineralization disorders |
| MX368531B (es) | 2010-07-28 | 2019-10-07 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. |
| CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| SG11201401605QA (en) * | 2011-10-19 | 2014-09-26 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2014031646A2 (en) | 2012-08-20 | 2014-02-27 | Gliknik Inc. | Molecules with antigen binding and polyvalent fc gamma receptor binding activity |
| PL3097189T3 (pl) | 2014-01-24 | 2018-11-30 | Am-Pharma B.V. | Chimeryczne białka podobne do alkalicznej fosfatazy |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| CA2967851C (en) | 2014-12-05 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| MX394116B (es) | 2015-07-24 | 2025-03-19 | Gliknik Inc | Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada. |
| RU2745528C2 (ru) * | 2015-08-17 | 2021-03-26 | Алексион Фармасьютикалз, Инк. | Производство щелочных фосфатаз |
| WO2017058822A1 (en) * | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| JP7613826B2 (ja) * | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
| WO2017171871A1 (en) * | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3464347B1 (en) | 2016-06-07 | 2023-05-31 | Gliknik Inc. | Cysteine-optimized stradomers |
| WO2018004517A1 (en) | 2016-06-27 | 2018-01-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children and adolescents |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| CA3045458A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| AU2017371179B2 (en) | 2016-12-09 | 2022-07-14 | Gliknik Inc. | Manufacturing optimization of GL-2045, a multimerizing stradomer |
| AU2017371182B2 (en) | 2016-12-09 | 2024-03-28 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent Fc compounds |
| WO2018164995A1 (en) * | 2017-03-09 | 2018-09-13 | Alexion Pharmaceuticals, Inc . | Glycoprotein manufacturing process |
| CA3057502A1 (en) * | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| EP3737750B1 (en) | 2018-01-09 | 2024-06-05 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| JP7214962B2 (ja) * | 2018-01-17 | 2023-01-31 | 東ソー株式会社 | アルカリホスファターゼ高発現動物細胞 |
| WO2019183209A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| US11638699B2 (en) | 2018-03-20 | 2023-05-02 | Theriva Biologics, Inc. | Intestinal alkaline phosphatase formulations |
| JP2021519590A (ja) * | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 糖タンパク質の製造 |
| CN110499284A (zh) * | 2018-05-17 | 2019-11-26 | 西安组织工程与再生医学研究所 | Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用 |
| EP3796941A4 (en) | 2018-05-30 | 2022-12-28 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| JP2021534111A (ja) | 2018-08-10 | 2021-12-09 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法 |
| CA3137045A1 (en) | 2019-05-06 | 2020-11-12 | Synthetic Biologics, Inc. | Alkaline phosphate-based oncology treatments |
| US12433938B2 (en) * | 2019-12-09 | 2025-10-07 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| US12478662B2 (en) | 2020-01-03 | 2025-11-25 | The United States of America as represented by the Secretary Department of Heath and Human Services | TNAP locally administered for promoting periodontal health |
| WO2022051555A2 (en) * | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
| KR102571967B1 (ko) * | 2021-01-21 | 2023-08-30 | 주식회사 마라나노텍코리아 | Alp 측정용 바이오 센서 |
| AU2022218782A1 (en) | 2021-02-12 | 2023-08-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| CA3263089A1 (en) * | 2022-08-31 | 2024-03-07 | Univ Utah Res Found | GJA1-20K COMPOSITIONS AND METHODS FOR MITIGATING ISCHEMIC-REPERFUSION INJURY |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7008A (en) * | 1850-01-08 | Improvement in alloys for points of lightning-rods | ||
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
| EP1395293B1 (en) | 2001-05-14 | 2009-07-22 | Gbp Ip, Llc | Lentiviral vectors encoding clotting factors for gene therapy |
| CA2433479A1 (en) | 2002-07-22 | 2004-01-22 | F. Hoffmann-La Roche Ag | Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof |
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| US20070081984A1 (en) * | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| BRPI0512496A (pt) | 2004-06-23 | 2008-03-04 | Genzyme Corp | processos e composições para o tratamento de doenças policìsticas |
| US20090142347A1 (en) * | 2004-09-29 | 2009-06-04 | The Burnham Institute For Medical Research | Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification |
| JP2008521575A (ja) | 2004-12-01 | 2008-06-26 | ジェンザイム・コーポレイション | 肝臓を標的とした遺伝物質の送達方法 |
-
2008
- 2008-05-12 PL PL08757088T patent/PL2158319T4/pl unknown
- 2008-05-12 DK DK08757088.3T patent/DK2158319T3/da active
- 2008-05-12 RS RS20140237A patent/RS53302B/sr unknown
- 2008-05-12 EP EP13002327.8A patent/EP2662448B1/en active Active
- 2008-05-12 EP EP11004496.3A patent/EP2368999B1/en active Active
- 2008-05-12 BR BRPI0811198A patent/BRPI0811198B8/pt active IP Right Grant
- 2008-05-12 AT AT08757088T patent/ATE536413T1/de active
- 2008-05-12 ES ES08757088T patent/ES2380546T3/es active Active
- 2008-05-12 SI SI200831780A patent/SI2662448T1/sl unknown
- 2008-05-12 DK DK13002327.8T patent/DK2662448T3/en active
- 2008-05-12 EP EP08757088A patent/EP2158319B1/en active Active
- 2008-05-12 HU HUE13002327A patent/HUE031655T2/hu unknown
- 2008-05-12 ME MEP-2014-48A patent/ME01828B/me unknown
- 2008-05-12 ES ES11004496.3T patent/ES2471915T3/es active Active
- 2008-05-12 PT PT110044963T patent/PT2368999E/pt unknown
- 2008-05-12 WO PCT/CA2008/000923 patent/WO2008138131A1/en not_active Ceased
- 2008-05-12 PL PL13002327T patent/PL2662448T3/pl unknown
- 2008-05-12 BR BR122019000505-2A patent/BR122019000505B1/pt active Search and Examination
- 2008-05-12 DK DK11004496.3T patent/DK2368999T3/da active
- 2008-05-12 ES ES13002327T patent/ES2619332T3/es active Active
- 2008-05-12 US US12/599,679 patent/US20100297119A1/en not_active Abandoned
- 2008-05-12 PT PT130023278T patent/PT2662448T/pt unknown
- 2008-05-12 DE DE202008018131U patent/DE202008018131U1/de not_active Expired - Lifetime
- 2008-05-12 PL PL11004496T patent/PL2368999T3/pl unknown
- 2008-05-12 CA CA2687001A patent/CA2687001C/en active Active
- 2008-05-12 SI SI200831200T patent/SI2368999T1/sl unknown
- 2008-05-12 JP JP2010507770A patent/JP5732603B2/ja active Active
- 2008-05-12 AU AU2008250945A patent/AU2008250945B2/en active Active
- 2008-05-12 PT PT08757088T patent/PT2158319E/pt unknown
-
2009
- 2009-11-11 IL IL202057A patent/IL202057A0/en unknown
-
2014
- 2014-05-08 HR HRP20140416AT patent/HRP20140416T1/hr unknown
-
2016
- 2016-01-15 HU HUS1600005C patent/HUS1600005I1/hu unknown
- 2016-01-28 LT LTPA2016004C patent/LTC2368999I2/lt unknown
- 2016-02-02 NO NO2016002C patent/NO2016002I2/no not_active IP Right Cessation
- 2016-02-10 LU LU92976C patent/LU92976I2/xx unknown
- 2016-02-19 FR FR16C0007C patent/FR16C0007I2/fr active Active
- 2016-02-23 CY CY2016005C patent/CY2016005I1/el unknown
- 2016-02-26 NL NL300798C patent/NL300798I1/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526543A5 (enExample) | ||
| HRP20140416T1 (hr) | Alkalna fosfataza koja je usmjerena na kosti, pribor i postupci uporabe | |
| JP6542433B2 (ja) | 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用 | |
| Baldo | Side effects of cytokines approved for therapy | |
| US9527901B2 (en) | Recombinant bi-functional fusion proteins, preparations and methods for treating disease | |
| ES2342820T3 (es) | Anticuerpos del opgl. | |
| EP3287470B1 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
| ES2539778T3 (es) | Proteínas de fusión humanas recombinantes de EPO-Fc con vida media prolongada y actividad eritropoyética in vivo mejorada | |
| ES2579906T3 (es) | Formulaciones de ADAMTS13 líquidas y liofilizadas estabilizadas | |
| BR112020026862A2 (pt) | antagonistas antitumorais de reguladores de pontos de verificação imunológica | |
| TWI705822B (zh) | 包含纖維蛋白溶酶原之醫藥組合物及其用途 | |
| TW201200152A (en) | Novel antibody formulation | |
| BRPI0710508B1 (pt) | composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído | |
| EA014232B1 (ru) | Стабильные белковые препараты | |
| TW201021826A (en) | Stabilized receptor polypeptides and uses thereof | |
| EA033788B1 (ru) | Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина | |
| CN102711733A (zh) | 瞬时连接于聚合物载体的干生长激素组合物 | |
| CN107787328B (zh) | 用于治疗血友病的截短的血管性血友病因子多肽 | |
| KR20180094114A (ko) | 돌연변이된 절단된 폰 빌레브란트 인자 | |
| KR20170026580A (ko) | 변형된 폰 빌레브란트 인자 | |
| US20030017151A1 (en) | Therapeutic use of rank antagonists | |
| ES2912300T3 (es) | Procedimientos de preparación de factor von Willebrand modificado | |
| JP2017537155A (ja) | 選択的ｉｌ−６−トランス−シグナル伝達阻害剤の投与 | |
| ES2869339T3 (es) | Polipéptidos del factor von Willebrand truncados para el tratamiento de la hemofilia | |
| US20220287347A1 (en) | Peptides for treating muscle atrophy |